Ughhh. This board has become so filled with useless posts by useless people that I'm going to take a break from it.
If their aim is to stop all valid discussions, they's succeeded, at least in my case. But if their aim is to get me (us) to sell shares, they are woefully misguided. I'll be back when the dust settles.
Sentiment: Strong Buy
IMO, there's only one or two actual bashers who post using different aliases. They all show up around the same time and their vocabularies and sentence structure are very similar. I have them all on Ignore so as far as I'm concerned, he/they can bash away.
Now that doesn't mean I necessarily believe Chugai is totally out of the picture. There are too many unknowns to say that. They may continue with the same partnership, with or without modified terms. They may be interested in the oncology potential of MultiStem and be willing to continue a partnership in that area only. Who knows? Certainly none of us here.
In my mind, it ain't over until the fat lady (Chugai) sings.
Again with the stupid YouTube videos? I find it interesting that every time someone calls you on something, you post a link to a YouTube video that you believe illustrates your point. It doesn't and it just makes you look foolish.
Ray, Chugai is a Japanese company with Japanese values. Honor is important to their culture and holding off any announcement until Athersys is ready would be the honorable thing to do.
Twisted logic there. I don't believe that even if Chugai is out, Japan is also out. Gil stated that there were other Japanese companies interested in MultiStem and I tend to believe him. Perhaps Athersys is already negotiating with one or more alternate companies. I also believe Chugai is an honorable company and may be withholding any announcement until Athersys is in a better position with an alternate partner.
According to Daiichi Sankyo's website:
"To expand our business, we're partnering on promising products that complement our in-house portfolio and will help us achieve long-term growth. Our strategy involves acquiring new products and product candidates, and companies that will drive our portfolio in key therapeutic areas. Our decades-long history of effective collaboration exemplifies our ability to license products in and out of Daiichi Sankyo, develop and maintain valuable partnerships, and successfully complete mergers and acquisitions."
In some respects, I agree with scistats. More and more, it looks like Chugai is going to opt out. But that may be a good thing. Daiichi Sankyo appears to be a better fit, with the company's concentrations on anti-inflammatories, cardiovascular diseases, metabolic diseases and especially on stroke treatments.
According to the contract between Athersys and Chugai, Athersys has the right to negotiate with other companies in Japan up to the date Chugai makes the $7M payment. There is an excellent possibility that's what is happening and I tend to believe Daiichi Sankyo could be at least among the alternatives.
Daiichi Sankyo is a global pharmaceutical company headquartered in Japan - check.
Daiichi Sankyo is the second largest pharmaceutical company in Japan - check.
Daiichi Sankyo has a couple of clinical trials for Ischemic Stroke:
1. DS-1040 TAFIa inhibitor Acute ischemic stroke - P1
2. Prasugrel Anti-platelet agent Ischemic stroke - P3
They also have a number of trials ongoing in related areas but apparently no current links to regenerative medicine. With the new RM law in Japan and the competition either hooking up with RM companies or working on their own products, it makes excellent sense for Daiichi Sankyo to align themselves with Athersys.
Sentiment: Strong Buy
So essentially, Gil brought the entire sector down, according to your comment. I'm impressed! I didn't know he had so much influence.
Oh, you have been called on your misleading and inflammatory posts many times. Not only for your fake news article but for your constant flip-flopping and misleading statements. Do you think all of us have short memories?
Sure, well after a number of us called you on it. I can't take away your posting privileges, but what I can do is warn orhers about you. You typically atart out posting legitimate information and/or well thought out statements, then over time, your posts get more and more negative and even bizarre. Then you disappear for a while and repeat the process. You've done that at least 3-4 times since I started watching ATHX.
Obviously fictional? I remember that post too. You never indicated it was speculation or meant as a fictional possibility. You posted it as if it was a legitimate news story.
Hardly. Of all the anticoagulants on the market, Warfarin is the only one that is off-patent. Roche has plenty of competition from generic drug makers.
As far as the genetic markers are concerned, there is still a lot of debate about the usefulness of DNA testing to indicate a risk to people for most medical conditions. The FDA themselves issued a ruling banning DNA self-testing companies like 23andMe and AncestryDNA from including medical information in their tests. 23andMe was recently allowed to test for Bloom syndrome, a rare autosomal recessive disorder characterized by short stature, predisposition to the development of cancer and genomic instability, but the FDA has left in place the ban on all other medical uses.
It will take many years before science understands the significance of genetic markers and how they may indicate an increased danger of people experiencing certain medical conditions and how accurate the tests themselves are in predicting the likelihood of people suffering from them. Even stroke risk has a huge number of possible causes, only very few of which are genetic in nature. Age, race, gender, heredity, high blood pressure, diabetes, artery diseases, afib and other heart diseases, sickle cell disease, high cholesterol, poor diet, obesity and inactivity are among the known risk factors. Only heredity may link to DNA tests.
Now as to why your assumption is ludicrous:
1. Only a relatively small percentage of stroke victims had known preexisting stroke risk indications like afib, embolisms ,etc. that indicate the use of oral anticoagulants.
2. Only Warfarin/Coumadin users benefit from frequent monitoring to maintain optimal dosing.
3. Newer anticoagulants like Pradaxa, Xarelto, Eliquis, and Savaysa are replacing Warfarin and none of them need frequent monitoring.
So, Roche, who makes both Warfarin and the CoaguChek system is losing market share for those products. Your thinking is deeply flawed.
"Front end consumer diagnostics for stroke prevention"? That is actually hilarious! I assume you're talking about Roche's CoaguChek product.
"To be eligible for home INR testing under Medicare or most private insurance, you must be diagnosed with one or more of the following diagnosis:
Mechanical Heart Valve (MHV)
Venous Thromboembolism, Deep Vein Thrombosis (DVT), or Pulmonary Embolism (PE)
You must also meet the following criteria:
Have been taking warfarin or a brand of warfarin such as Coumadin® for at least 90 days (or 3 months)
Be physically capable of performing a test by taking a fingerstick blood sample or have a caregiver that could assist you
Be able to demonstrate the correct use of the home INR monitor after training"
- continued -